A comparison of the effects of oral dydrogesterone and levonorgestrel-releasing intrauterine device on quality of life and sexual function in patients with abnormal uterine bleeding

Arch Gynecol Obstet. 2024 Feb;309(2):715-719. doi: 10.1007/s00404-023-07315-y. Epub 2023 Dec 27.

Abstract

Objective: The purpose of this study is to compare the effects of cyclic oral dydrogesterone treatment and levonorgestrel-releasing intrauterine device (LNG_IUD) on quality of life (QoL) and sexual function in patients diagnosed with abnormal uterine bleeding (AUB).

Study design: The study was conducted at the University of Health Sciences Turkey Health Istanbul Kanuni Sultan Süleyman Training and Research Hospital, on 171 sexually active patients, aged 18-45, who were under a minimum of 6 months of treatment for AUB. 85 patients were treated with oral cyclic dydrogesterone, and 86 patients received LNG-IUD. Following a minimum of 6 months of treatment, these patients were recruited to the study and were asked to complete a 36-Item Short Form Survey (SF-36) and the Female Sexual Function Index (FSFI).

Results: When the FSFI scores of the patients were compared, it was observed that the total FSFI score was significantly higher in the cyclic dydrogesterone group (p < 0.05). Likewise, it was observed that sexual desire, arousal, and lubrication domains were significantly higher in the cyclic dydrogesterone group (p < 0.05). No significant differences were found between the treatment groups in 7 out of the 8 dimensions of SF-36. The energy/vitality dimension was found to be significantly higher in the cyclic dydrogesterone group.

Conclusion: Total FSFI score, as well as sexual desire, arousal, and lubrication scores, were significantly higher in the cyclic dydrogesterone group compared to the LNG-IUD group indicating that cyclic dydrogesterone has a more positive impact on sexual function when compared to LNG-IUD.

Keywords: Abnormal uterine bleeding; Dydrogesterone; FSFI; LNG-IUD; Quality of life; SF-36.

MeSH terms

  • Contraceptive Agents, Female*
  • Dydrogesterone
  • Female
  • Humans
  • Intrauterine Devices, Medicated*
  • Levonorgestrel
  • Quality of Life
  • Uterine Hemorrhage / drug therapy
  • Uterine Hemorrhage / etiology

Substances

  • Levonorgestrel
  • Dydrogesterone
  • Contraceptive Agents, Female